Increasing evidence suggests that multiple factors can produce effects on the immature brain that are distinct and more long-lasting than those produced in adults. The hypothalamic paraventricular nucleus (PVN) is a region integral to the hypothalamic-pituitary-adrenal axis and is affected by anxiety, depression, and drugs used to treat these disorders, yet receptor signaling mechanisms operative in hypothalamus prior to maturation remain to be elucidated. In peripubertal male rats, systemic injection of the selective serotonin 1A (5-HT 1A ) receptor agonist (þ)8-OH-DPAT (0.2 mg/kg) markedly elevated plasma levels of oxytocin and adrenocorticotropic hormone (ACTH) at 5 and 15 min post-injection. The 5-HT 1A receptor selectivity was demonstrated by the ability of the 5-HT 1A receptor selective antagonist WAY100635 to completely block both oxytocin and ACTH responses at 5 min, with some recovery of the ACTH response at 15 min. At 15 min post-injection, (þ)8-OH-DPAT also increased levels of phosphorylated extracellular signal-regulated kinase (pERK) and phosphorylated protein kinase B (pAkt) in the PVN. As previously observed in adults, (þ)8-OH-DPAT reduced levels of pERK in hippocampus. WAY100635 also completely blocked (þ)8-OH-DPAT-mediated elevations in hypothalamic pERK and pAkt and the reductions in hippocampal pERK, demonstrating 5-HT 1A receptor selectivity of both kinase responses. This study provides the first demonstration of functional 5-HT 1A receptor-mediated ERK and Akt signaling pathways in the immature hypothalamus, activated by a dose of (þ)8-OH-DPAT that concomitantly stimulates neuroendocrine responses. This information is fundamental to identifying potential signaling pathways targeted by biased agonists in the development of safe and effective treatment strategies in children and adolescents.
Introduction
The hypothalamic-pituitary-adrenal (HPA) axis receives messages from the brain and body to coordinate responses to both psychological and physiological stressors (Carrasco and Van de Kar, 2003; Sullivan Hanley and Van de Kar, 2003; Jorgensen, 2007; Pompili et al., 2010) . The paraventricular nucleus (PVN) is one of several hypothalamic nuclei that are pivotal to regulating HPA function. Previous studies, primarily carried out in adult animal models, have shown that serotonergic input to the hypothalamic PVN activates postsynaptic serotonin 1A (5-HT 1A ) receptors on hormone-containing cells. This activation results in increases of plasma levels of various stress hormones, such as oxytocin and adrenocorticotropic hormone (ACTH) (Pan and Gilbert, 1992; Bagdy, 1996) . Increasing evidence supports an involvement of 5-HT 1A receptors in anxiety and depression (Celada et al., 2013; Albert and Fiori, 2014; Jiang et al., 2014; GarciaGarcia et al., 2016) . Consistent with this association, antidepressant treatment alters both HPA function and its regulation by serotonergic neurons (Li et al., 1996 (Li et al., , 1997 Lerer et al., 1999; Serres et al., 2000a; Young et al., 2004; Modell and Holsboer, 2005; Conti et al., 2007; Papiol et al., 2007; Thomson and Craighead, 2008; Bao et al., 2008; Holsboer and Ising, 2010) . Thus, investigating the signaling mechanisms of 5-HT 1A receptors in the hypothalamic PVN can contribute to a better understanding of how antidepressants alter HPA functioning and subsequent positive treatment outcomes.
In the adult rat hypothalamus, postsynaptic 5-HT 1A receptors not only elevate plasma levels of oxytocin and ACTH, but also increase levels of the phosphorylated mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase (ERK) (Sullivan et al., 2005; Crane et al., 2007) . Neuroadaptative changes in both neuroendocrine responses and kinase signaling have also been associated with stress, depression, and the effects of antidepressant medications (Shen et al., 2004; Qi et al., 2006; Gourley et al., 2008) . For example, in adult rats, chronic treatment with fluoxetine, the prototypical selective serotonin reuptake inhibitor (SSRI), desensitizes postsynaptic 5-HT 1A receptor-mediated neuroendocrine responses via reductions in levels of hypothalamic Gaz proteins (Raap et al., 1999) . Additionally, in adult mice, acute blockade of ERK signaling via systemic administration of a MAPK kinase (MEK) inhibitor, produces a depressive-like phenotype and blocks behavioral actions of antidepressants (Duman et al., 2007) . Studies in adult rodents have demonstrated that paradigms that produce a depressive-like phenotype, such as chronic social defeat stress (Iio et al., 2011) and chronic unpredictable mild stress (Zhao et al., 2017) , reduce levels of pERK in hippocampus and ventrolateral orbital cortex, respectively. In adult animals, 5-HT 1A receptors activate ERK in various brain regions including the hypothalamus (Chen et al., 2002; Sullivan et al., 2005; Crane et al., 2007) , suggesting hypothalamic ERK may play a role in the actions of antidepressant drugs in adults. Indeed, we have reported that, in adult rats, inhibition of ERK in the hypothalamic PVN prevents fluoxetine-induced desensitization of 5-HT 1A receptor-mediated hormone responses (Jia et al., 2007) . With respect to MAPK function in the immature brain, one study in neonatal mice indicated that 5-HT 1A receptor-activated ERK may be involved in antidepressant-mediated hippocampal neurogenesis (Mogha et al., 2012) . Although this suggests a similar MAPK signaling pathway may be present in the immature brain, no studies have addressed this issue, nor have any studies delineated other kinase signaling pathways present in the immature brain, such as the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway.
Multiple lines of evidence indicate that the PI3K/Akt pathway plays a role in the pathology of psychological disorders, including chronic stress and depression. For example, in adult animals subjected to chronic stress, increased levels of activated Akt have been found in various brain regions (Lee et al., 2006) and, in human suicide victims, the activity of both PI3K and Akt were significantly decreased in the occipital cortex when compared to controls (Hsiung et al., 2003) . In vitro studies in cell lines or primary cultures have indicated that 5-HT 1A receptors can activate the PI3K/Akt pathway and increase phosphorylation of its downstream target, glycogen synthase kinase-3b (GSK3b) (Adayev et al., 1999; Li et al., 2004; Cowen et al., 2005; Hsiung et al., 2005) . While a few studies have reported the involvement of 5-HT 1A receptors with Akt activation in adults (Polter et al., 2012; Islam et al., 2014; Popovic et al., 2015) , no studies have determined, in an in vivo model, whether 5-HT 1A receptor-mediated phosphorylation of Akt is present in the immature brain, particularly in the hypothalamic PVN.
In light of the prominent role of the hypothalamus in development and HPA function, there remains a paucity of information on the mechanisms of hypothalamic serotonin receptor signaling prior to maturation (i.e., the peripubertal period). Additionally, given the role of the hippocampus in exerting negative feedback on HPA activation (Zhu et al., 2014) and hippocampal 5-HT 1A receptor involvement in mediating antidepressant responses (Samuels et al., 2015) , we sought to elucidate whether 5-HT 1A receptors also alter ERK signaling in the immature hippocampus.
Given the capacity of 5-HT 1A receptors to signal via a multiplicity of effector mechanisms (Raymond et al., 2001) , with the specificity of receptor/effector coupling being dependent on the specific cell type or brain region investigated, developmental age is also likely to be a determinant in the nature of 5-HT 1A receptor coupling to functional downstream effectors in the immature brain. Although SSRIs are prescribed as the most effective pharmacological treatment of mood disorders in children and adolescents, this remains controversial given the association of SSRI treatment with increased suicidal thoughts or behavior in these age groups (Gordon and Melvin, 2013) . A recent study suggested that 5-HT 1A receptors are involved in the expression of negative side effects, such as suicide-related events, associated with antidepressant use (Rahn et al., 2015) . Therefore, identifying the 5-HT 1A signaling mechanism(s) that are operative prior to maturation and their role in stress, depression, or medication effects is fundamental to better understanding and treating mood disorders in children and adolescents.
Consequently, the purpose of the current study was to investigate whether the mechanisms of 5-HT 1A receptor signaling previously reported in adults is also operative in the peripubertal rat hypothalamic PVN and hippocampus. Based on previous studies in adult rodents (Crane et al., 2007) , we hypothesized that 5-HT 1A receptor activation in the peripubertal rat will be functional with respect to (1) increasing plasma oxytocin and ACTH, (2) increasing in pERK and pAkt in hypothalamic PVN, and (3) reducing hippocampal pERK as observed in adults. The findings of this study may be clinically relevant with respect to the therapeutic efficacy and/or side effects of medications to treat depression and other mood disorders prior to maturation.
Material and methods

Animals
Peripubertal male SpragueeDawley rats (100e125 g, total N ¼ 80) were purchased from Harlan (Indianapolis, Indiana) and were delivered to the facility on postnatal day 40. The determination of postnatal day 0 (day of birth) was carried out by the supplier. All animals had 2e3 days to acclimate to their home cage before handling and were housed two per cage in a room controlled for temperature (20e22 C), humidity (50e55%), and illumination (12h:12h light/dark cycle; lights on at 07:00h). Food and water were available ad libitum. All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals as approved by Loyola University Institutional Animal Care and Use Committee. Every effort was made to minimize suffering and discomfort to the animals. The number of rats per group was the minimum needed for statistically meaningful evaluation of the data. At least 3 days of handling preceded any injections.
Drugs/materials
cyclohexanecarboxamide (WAY100635) was a gift from WyethAyerst (Princeton, New Jersey). (þ)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide ((þ)8-OH-DPAT) was purchased from Tocris Cookson Inc. (Ellisville, Missouri, USA). Drugs were dissolved in saline (0.9% NaCl; 1 ml/kg) and were prepared immediately prior to the injections.
Experiment
Peripubertal male Sprague-Dawley rats (postnatal day 47) were given a systemic pretreatment injection of either saline (1 ml/kg, s.c.) or WAY100635 (0.1 mg/kg, s.c.). The dose of WAY100635 (0.1 mg/kg, s.c.) was chosen due to its effectiveness in blocking 8-OH-DPAT-mediated responses in adult rats in a previously published study (Li et al., 1999) . Thirty minutes later, rats received a systemic challenge injection with either saline (1 ml/kg, s.c.) or (þ) 8-OH-DPAT (0.2 mg/kg, s.c.), and were sacrificed by decapitation 5 or 15 min after challenge injection. The post-challenge injection sacrifice times were chosen based on a previously published study that indicated robust but transient 5-HT 1A receptor-mediated increases in pERK in the adult rat PVN and significant decreases in 5-HT 1A receptor-mediated pERK responses in the hippocampus (Crane et al., 2007) . The brains were carefully removed from the skull within one minute of the decapitation and were quickly frozen by submersion in chilled 2-methylbutane (À35 C) for 1 min and then subsequently kept in dry ice for an additional 10 min. Each brain was then securely wrapped and stored at À80 C. The PVN and hippocampus were dissected as detailed in Crane et al. (2007) . The trunk blood was collected in tubes containing 0.25 ml of 0.3 M EDTA (pH 7.4) and was subsequently centrifuged. Plasma was aliquoted and stored at À80 C for assessment of hormone levels.
Hormone assays
Plasma oxytocin and ACTH were determined by radioimmunoassay as previously described in detail (Li et al., 1993 (Li et al., , 1997 .
125 Ioxytocin was purchased from PerkinElmer-NEN (Boston, MA, USA) and 125 I-ACTH was purchased from DiaSorin, Inc. (Stillwater, MN, USA). The sensitivity limit of the oxytocin assay is 1 pg/tube, and the intra-and interassay variabilities are 8.1% and 8.6%, respectively (Li et al., 1997) . The sensitivity limit for the ACTH assay is 0.2 pg/ tube, and the intra-and interassay variabilities are 4.8 and 13.6%, respectively (Li et al., 1993) .
Western blotting
Levels of phosphorylated ERK (pERK) and ERK in the PVN and hippocampus were determined by western blotting according to previously described procedures (Crane et al., 2007) . Separate gels run in parallel were used to determine pERK and ERK values, then the blots containing the PVN samples were stripped and reincubated with phosphorylated Akt (pAkt) and Akt antibodies to determine pAkt and Akt levels. For quantification, all phosphorylated proteins were normalized to the respective unphosphorylated protein levels, which were unchanged by any of the treatments (data not shown). Quantification of pERK was restricted to the p42 isoform, as the p44 isoform was often not visible. Primary antibodies (and concentrations) used: rabbit anti-p44/42 MAP kinase antibody (1:1000), mouse anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (1:2000), rabbit anti-Akt antibody (1:1000), rabbit anti-phospho-Akt antibody (Ser473) (1:1000); Cell Signaling Technology, Beverly, MA.
Data analysis
The data are presented as group means (n ¼ 6e8) and the standard errors of the mean (SEM). Any values ± 2 SD of the group averages were considered outliers and were excluded from analyses. All data were analyzed by 2-way analysis of variance (ANOVA). Group means were compared by a Tukey post-hoc test. JASP software (https://jasp-stats.org/) was used for all statistical analyses.
Results
5-HT 1A receptors mediate (þ)8-OH-DPAT-induced increases in the plasma levels of oxytocin in peripubertal rats
(þ)8-OH-DPAT markedly increased plasma levels of oxytocin over saline at both 5 and 15 min post-challenge injection. Pretreatment with the 5-HT 1A receptor antagonist WAY100635 completely blocked (þ)8-OH-DPAT-mediated increases in plasma levels of oxytocin at both 5 and 15 min. Pretreatment with WAY100635 and subsequent challenge with saline did not alter basal levels of plasma oxytocin at either time point (Fig. 1) .
The two-way ANOVA for 5-HT 1A receptor-mediated increases of oxytocin levels at 5 min indicated a significant main effect of pretreatment (F 1,27 ¼ 33.17, p < 0.001) and a significant main effect of challenge (F 1,27 ¼ 33.89, p < 0.001). There was also a significant interaction between pretreatment and challenge (F 1,27 ¼ 31.81, p < 0.001). A Tukey post-hoc test indicated that (þ)8-OH-DPAT significantly (p < 0.001) increased oxytocin levels compared to saline challenge in saline-pretreated animals, and that the (þ)8-OH-DPAT-induced increase was significantly attenuated by pretreatment with WAY100635 (p < 0.001).
The two-way ANOVA for 5-HT 1A receptor-mediated increases of oxytocin levels at 15 min indicated a significant main effect of pretreatment (F 1,30 ¼ 52.83, p < 0.001) and a significant main effect of challenge (F 1,30 ¼ 73.36, p < 0.001). There was also a significant interaction between pretreatment and challenge (F 1,30 ¼ 54.54, p < 0.001). A Tukey post-hoc test indicated that (þ)8-OH-DPAT significantly (p < 0.001) increased oxytocin levels compared to saline challenge in saline-pretreated animals, and that the (þ)8-OH-DPAT-induced increase was significantly attenuated by pretreatment with WAY100635 (p < 0.001).
3.2. 5-HT 1A receptors mediate (þ)8-OH-DPAT-induced increases in the plasma levels of ACTH in peripubertal rats (þ)8-OH-DPAT markedly increased plasma levels of ACTH over saline at both 5 and 15 min post-challenge injection. Pretreatment with the 5-HT 1A receptor antagonist WAY100635 completely blocked (þ)8-OH-DPAT-mediated increases in plasma levels of ACTH at 5 min post-injection, but only partially blocked (þ)8-OH-DPAT-mediated increases in plasma levels of ACTH at 15 min postinjection. Pretreatment with WAY100635 and subsequent challenge with saline did not alter basal levels of plasma ACTH at either time point (Fig. 2) . The two-way ANOVA for 5-HT 1A receptor-mediated increases of ACTH levels at 5 min indicated a significant main effect of pretreatment (F 1,24 ¼ 101.44, p < 0.001) and a significant main effect of challenge (F 1,24 ¼ 85.37, p < 0.001). There was also a significant interaction between pretreatment and challenge (F 1,24 ¼ 101.14, p < 0.001). A Tukey post-hoc test indicated that (þ)8-OH-DPAT significantly (p < 0.001) increased ACTH levels compared to saline challenge in saline-pretreated animals, and that the (þ)8-OH-DPAT-induced increase was significantly attenuated by pretreatment with WAY100635 (p < 0.001).
The two-way ANOVA for 5-HT 1A receptor-mediated increases of ACTH levels at 15 min indicated a significant main effect of pretreatment (F 1,30 ¼ 14.64, p < 0.001) and a significant main effect of challenge (F 1,30 ¼ 88.85, p < 0.001). There was also a significant interaction between pretreatment and challenge (F 1,30 ¼ 14.83, p < 0.001). A Tukey post-hoc test indicated that (þ)8-OH-DPAT significantly increased ACTH levels in both saline-pretreated (p < 0.001) and WAY100635-pretreated (p ¼ 0.003) animals compared to the respective saline-challenged controls. However, the (þ)8-OH-DPAT-induced increase in plasma ACTH levels was significantly attenuated by pretreatment with WAY100635 (p < 0.001).
Thus, pretreatment with the 5-HT 1A receptor antagonist WAY100635 significantly reduced the (þ)8-OH-DPAT-mediated increases in plasma levels of ACTH at both post-challenge injection times, with complete blockade achieved at 5 min post-challenge injection but not at 15 min post-challenge injection.
3.3. 5-HT 1A receptors mediate (þ)8-OH-DPAT-induced increases in the phosphorylation of ERK in the PVN of peripubertal rats (þ)8-OH-DPAT markedly increased pERK in the PVN over saline at 15 min, but not 5 min, post-challenge injection. Pretreatment with the 5-HT 1A receptor antagonist WAY100635 completely blocked (þ)8-OH-DPAT-mediated increases in pERK in the PVN at 15 min post-challenge injection. Pretreatment with WAY100635 and subsequent challenge with saline did not alter basal levels of pERK in the PVN (Fig. 3) .
The two-way ANOVA for 5-HT 1A receptor-mediated increases pERK in PVN at 5 min indicated a significant main effect of pretreatment (F 1,21 ¼ 6.548, p ¼ 0.018), but no significant main effect of challenge (F 1,21 ¼ 0.666, p ¼ 0.424). There was also no interaction between pretreatment and challenge (F 1,21 ¼ 2.915, p ¼ 0.103). A Tukey post-hoc test indicated that the WAY100635-treated/(þ)8-OH-DPAT-challenged rats had significantly lower levels of pERK in the PVN compared to the saline-treated/(þ)8-OH-DPAT-challenged rats (p ¼ 0.035).
The two-way ANOVA for 5-HT 1A receptor-mediated increases pERK in the PVN at 15 min indicated a significant main effect of pretreatment (F 1,21 ¼ 7.262, p ¼ 0.014), but no main effect of challenge (F 1,21 ¼ 1.757, p ¼ 0.199). There was a significant interaction between pretreatment and challenge (F 1,21 ¼ 7.584, p ¼ 0.012). A Tukey post-hoc test indicated that (þ)8-OH-DPAT significantly (p ¼ 0.028) increased pERK levels in the PVN compared to saline challenge in saline-pretreated animals, and that the (þ)8-OH-DPAT-induced increase was significantly attenuated by pretreatment with WAY100635 (p ¼ 0.007).
3.4. 5-HT 1A receptors mediate (þ)8-OH-DPAT-induced reductions in the phosphorylation of ERK in the hippocampus of peripubertal rats (þ)8-OH-DPAT significantly decreased pERK in the hippocampus compared to saline at 15 min, but not 5 min, post-injection. Pretreatment with the 5-HT 1A receptor antagonist WAY100635 completely blocked (þ)8-OH-DPAT-mediated decreases in pERK in the hippocampus at 15 min post-injection. Pretreatment with WAY100635 and subsequent challenge with saline did not alter basal levels of pERK in the hippocampus (Fig. 4) .
The two-way ANOVA for 5-HT 1A receptor-mediated decreases in pERK in the hippocampus at 5 min indicated no significant main effect of pretreatment (F 1,21 ¼ 0.015, p ¼ 0.902) and no significant main effect of challenge (F 1,21 ¼ 2.403, p ¼ 0.136). There was also no interaction between pretreatment and challenge (F 1,21 ¼ 0.337, p ¼ 0.568). The two-way ANOVA for 5-HT 1A receptor-mediated decreases in pERK in the hippocampus at 15 min indicated a significant main effect of pretreatment (F 1,21 ¼ 5.272, p ¼ 0.032) and a main effect of challenge (F 1,21 ¼ 5.184, p ¼ 0.033). There was a trend toward a significant interaction between pretreatment and challenge (F 1,21 ¼ 3.782, p ¼ 0.065). A Tukey post-hoc test indicated that (þ)8-OH-DPAT significantly (p ¼ 0.029) decreased pERK levels in the hippocampus compared to saline challenge in saline-pretreated animals, and that the (þ)8-OH-DPAT-induced decrease was significantly blocked by pretreatment with WAY100635 (p ¼ 0.036).
5-HT 1A receptors mediate (þ)8-OH-DPAT-induced increases in the phosphorylation of Akt in the PVN of peripubertal rats
(þ)8-OH-DPAT significantly increased pAkt in the PVN over saline at 15 min, but not 5 min, post-injection. Pretreatment with the 5-HT 1A receptor antagonist WAY100635 completely blocked (þ)8-OH-DPAT-mediated increases in pAkt in the PVN at 15 min postinjection. Pretreatment with WAY100635 and subsequent challenge with saline did not alter basal levels of pAkt in the PVN (Fig. 5) .
The two-way ANOVA for 5-HT 1A receptor-mediated increases in pAkt in the PVN at 5 min indicated no significant main effect of pretreatment (F 1,20 ¼ 0.196, p ¼ 0.662) and no significant main effect of challenge (F 1,20 ¼ 1.526, p ¼ 0.231). There was also no interaction between pretreatment and challenge (F 1,20 ¼ 0.105, p ¼ 0.749).
The two-way ANOVA for 5-HT 1A receptor-mediated increases in pAkt in the PVN at 15 min indicated no significant main effect of pretreatment (F 1,22 ¼ 2.727, p ¼ 0.113) and a trend towards a main effect of challenge (F 1,22 ¼ 3.391, p ¼ 0.079). There was a significant interaction between pretreatment and challenge (F 1,22 ¼ 7.018, p ¼ 0.015). A Tukey post-hoc test indicated that (þ)8-OH-DPAT significantly (p ¼ 0.016) increased pAkt levels in the PVN compared to saline challenge in saline-pretreated animals, and that the (þ)8-OH-DPAT-induced increase was significantly attenuated by pretreatment with WAY100635 (p ¼ 0.035).
Discussion
The present study represents the first demonstration of 5-HT 1A receptor-mediated signaling of multiple hormone and kinase pathways in the hypothalamic paraventricular nucleus of the peripubertal brain. The peripubertal period of development is a time of accelerated growth, marked by an extensive amount of brain changes, neuroplasticity, and behavioral changes. Increasingly, research has shown that serotonergic systems may be particularly vulnerable to stress and drugs prior to maturation. Antidepressantinduced effects produced on the brain and behavior during this period can be long lasting and/or qualitatively and quantitatively distinct from those produced in adults (Ansorge et al., 2004; Maciag et al., 2006; Taravosh-Lahn et al., 2006; Oh et al., 2009) . Given the prominent role that serotonergic systems play in antidepressant efficacy and the differential effects of antidepressants administered to young versus adult animals, these findings suggest potential agedependent differences in serotonergic function.
To date, the majority of studies investigating serotonergic function have employed adult animal models that have focused primarily on regions such as hippocampus and cortex, two regions that have been implicated in mood disorders. In addition to the relevance of these regions, increased hypothalamic function also has been implicated in depressive disorders and antidepressants can normalize HPA function (Lerer et al., 1999; Serres et al., 2000a; Young et al., 2004; Modell and Holsboer, 2005; Conti et al., 2007; Papiol et al., 2007; Thomson and Craighead, 2008; Bao et al., 2008; Holsboer and Ising, 2010) . We have previously shown that, in adult rats, SSRI antidepressants such as fluoxetine and paroxetine desensitize 5-HT 1A receptor-mediated hormone responses. This desensitization is associated with reductions in membrane levels of Gaz, the cogent subtype mediating the hormone responses to 5-HT 1A receptors (Li et al., 1993 (Li et al., , 1997 Serres et al., 2000b) . Few, if any, studies have investigated peripubertal serotonin receptor signaling in whole hypothalamus or discrete regions of the hypothalamus, such as the PVN, a key player in mediating hormonal responses to various stressors and drugs. Consequently, the present study investigated the mechanisms of in vivo 5-HT 1A receptor signaling of neuroendocrine responses and kinase pathways in the peripubertal rat brain.
In addition to the activation of neuroendocrine responses, various studies have demonstrated 5-HT 1A receptor coupling to MAPK signaling pathways. In cell lines, the effects of 5-HT 1A receptor activation may be inhibitory and mediated via pertussis toxin-sensitive Gbg subunits (Garnovskaya et al., 1996; Kushwaha and Albert, 2005) . However, in adult rodents, we and others have shown that systemic injections with 5-HT 1A receptor agonists can either stimulate or inhibit the phosphorylation of ERK depending on brain region (Chen et al., 2002; Sullivan et al., 2005; Crane et al., 2007) . Consistent with the reported findings in adult brains, the present study demonstrates that comparable mechanisms are operational in the peripubertal brain, as 5-HT 1A receptor activation similarly increases pERK in the PVN and concomitantly decreases pERK in the hippocampus. While there is some evidence that these region-specific differences in adults may be due to the respective activation of postsynaptic versus somatodendritic 5-HT 1A autoreceptors, the present study establishes that regional differences in adult brain 5-HT 1A receptor-mediated MAPK responses are established prior to sexual maturation. Therefore, biased agonists able to differentially target presynaptic versus postsynaptic 5-HT 1A receptors in the adult brain (Becker et al., 2016) are likely to produce comparable effects on these respective populations of 5-HT 1A receptors prior to sexual maturation.
In addition to the differential targeting of agonists to different populations of 5-HT 1A receptors, some agonists may exhibit functional selectively or preferential activation or enhancement of certain intracellular signal transduction pathways via based agonism of the same population of 5-HT 1A receptors (Celada et al., 2013; Chilmonczyk et al., 2015; Becker et al., 2016) . The differential agonist-dependent, cellular, and/or regional specificity in the regulation of kinase responses by 5-HT 1A receptors highlight the importance of identifying potential developmental differences in the characteristics of 5-HT 1A receptor-mediated signaling cascades. Indeed, it has been reported that there is a differential function of MAPK/ERK signaling in young and adult phases of life with respect to GABAergic function and the development of anxiety and depression (Wefers et al., 2012) . We report herein the first in vivo demonstration of the concomitant 5-HT 1A receptor-mediated activation of ERK and Akt in the peripubertal hypothalamic PVN via systemic injection of (þ)8-OH-DPAT. These data demonstrate the functionality of multiple 5-HT 1A receptor-mediated kinase pathways present prior to maturation and the possibility that some drugs may exhibit biased agonism for one of the multiple pathways. This study demonstrating that the same dose of the selective 5-HT 1A receptor agonist (þ)8-OH-DPAT markedly elevates multiple plasma hormone responses and concomitantly activates MAPK/ERK and Akt pathways in hypothalamic PVN also indicates that (þ)8-OH-DPAT is not a biased agonist for any of the identified pathways in the peripubertal hypothalamus. The complete attenuation of the (þ)8-OH-DPAT-induced increases in pERK and pAkt in the PVN and plasma levels of oxytocin at both post-injection time points, as well as plasma levels of ACTH at 5 min post-injection, by pretreatment with WAY100635 is consistent with these all being 5-HT 1A receptor-mediated responses. The less robust attenuation of the ACTH response at 15 min post-injection is likely due to a small degree of recovery from receptor blockade at this time due to pharmacokinetics and to the large amplification involved in the resulting plasma levels of ACTH. Given the large receptor reserve mediating the increases in plasma levels of ACTH (i.e., 5-HT 1A receptors stimulate the release of corticotropin releasing hormone (CRH), which activates pituitary CRH receptors to release ACTH into the bloodstream), levels of ACTH would be the most responsive to being elevated if even only a small number of receptors recovered from WAY100635 blockade at the 15 min post-injection time. This explanation is strengthened by the finding that WAY100635 completely blocked all (þ)8-OH-DPAT-mediated increases in plasma hormones and kinase responses at 5 min post-injection. As (þ)8-OH-DPAT can also act on 5-HT 7 receptors in the hypothalamus (Sprouse et al., 2004) , one could speculate that activation of 5-HT 7 receptors were responsible for the ACTH levels at 15 min postinjection (i.e. the "partial" blockade). However, if this were the case, WAY100635 would have also produced only partial blockade of ACTH at the 5-minute post-injection time.
The results presented in the current study also reveal some minor differences in hormone responses and kinase signaling pathways from respective responses previously observed in adults (Li et al., 1993; Crane et al., 2007) . For example, the magnitude of 5-HT 1A receptor-mediated increases in ACTH in peripubertal rat observed in the current study are comparable to those in levels observed in previously published studies in adult rats (e.g., Li et al., 1993) . However, in peripubertal rats, the 5-HT 1A receptor-mediated increases in oxytocin observed in this study are greater than what has been reported in adults (Li et al., 1993) . Developmental differences in sertonergic control of the magnitude of plasma hormone responses are likely part of a larger developmental shift to more mature responses to stress, such has been demonstrated for stressinduced HPA activation and oxytocin responses across adolescence (Jankord et al., 2011) . Additionally, although we demonstrate that 5-HT 1A receptor-mediated signaling pathways observed in the adult are also functional in the peripubertal brain, the current study suggests there may be differences with regards to the time course of these responses. In previously published studies examining 5-HT 1A receptor activation in adult rat PVN, there is an increase in 5-HT 1A receptor-mediated ERK phosphorylation in the PVN at 5 min with a return to basal levels at 15 min post-injection, suggesting a transient activation of ERK (Crane et al., 2007) . In the peripubertal hypothalamic PVN, 5-HT 1A receptor-mediated ERK phosphorylation was not observed at 5 min, but was significantly elevated at 15 min post-injection. This suggests possible developmental differences in the time of onset and/or longevity of ERK activation. This may be due to differential populations or numbers of G-protein subtypes that may need to be recruited to activate ERK in the peripubertal versus adult hypothalamic PVN. Alternatively, age-dependent shifts in the availability of other second messenger proteins may shape the coupling of receptors to effectors during development. For example, manipulations of b-arrestin isoforms alter functional selectivity of glutamatergic signaling pathways in a model of developmental neurotoxicity (Wang et al., 2016) . Another possibility is that there are developmental pharmacokinetic differences or possibly developmental alterations in PVN sensitivity to serotonergic agonists, as previously observed in various limbic regions of peripubertal and adult rats (Arrant et al., 2013) . Given the involvement of serotonin and MAPK in depressive behaviors and antidepressant drug effects in adult preclinical models, further in vivo studies examining peripubertal and adult rats in the same cohort are warranted to delineate the functional significance and timing of this kinase signaling pathway. The results of the current study suggest that baseline functions and neuroadaptive mechanisms induced by antidepressant treatment may differ in immature versus adult populations, potentially resulting in alterations in the treatment efficacy, side effects, or duration of drug effects.
The present study is also the first to demonstrate that 5-HT 1A receptor-mediated phosphorylation of Akt is functional in the peripubertal hypothalamus in vivo. Only recently have there been reports of 5-HT 1A receptor-mediated activation of Akt in mammalian central nervous system (Polter et al., 2012; Islam et al., 2014; Popovic et al., 2015) . Levels of glycogen synthase kinase 3b (GSK3b), a downstream target of Akt and mood stabilizers, has recently been shown to fluctuate in the cortex and hippocampus during early development (Beurel et al., 2012) , suggesting some developmental role for these fluctuations. As the ERK and Akt signaling pathways have been shown to play a role in the pathology and treatment of various psychological disorders that are prevalent during adolescence, the presence of these 5-HT 1A receptor-mediated kinase pathways in peripubertal hypothalamic PVN provide novel targets for drugs to treat these various clinical disorders prior to maturation.
Some new antidepressant agents, such as vortioxetine and vilazodone, are approved for use in adult populations and appear to demonstrate partial agonist properties at the 5-HT 1A receptor (Celada et al., 2013) . Given the multiplicity of 5-HT 1A receptormediated pathways activated in the hypothalamic PVN, it may be clinically relevant to determine if either drug exhibited any biased agonism for a given pathway in the peripubertal brain. Based on the current results, one might expect the clinical use of drugs with 5-HT 1A receptor activity may have some differential effects in pediatric/adolescent populations compared to adult populations. However, current data on pediatric or adolescent exposure to these drugs are extremely limited. One clinical trial examining vortioxetine use in pediatric patients suggested that this compound may be effective with a reduced amount of adverse events experienced by the subjects over time; however, the generalizability of these findings are limited by the small sample size of this study (Findling et al., 2018) . Although pediatric clinical usage of vilazodone has not been studied, accidental ingestion of this compound by children is associated with negative health consequences (Acker et al., 2015; Del Pizzo et al., 2018; Gaw et al., 2018) , especially in comparison to classic SSRIs (Russell et al., 2017) . These findings are not entirely unexpected, as a recent study suggested that negative side effects associated with antidepressant use appear to involve 5-HT 1A receptors (Rahn et al., 2015) .
Given the findings of the present study and the paucity of data on serotonin regulation of kinase signaling in the immature or adult hypothalamus, a variety of pertinent issues can now be addressed by subsequent studies. These questions include: (1) whether postsynaptic 5-HT 1A receptors specifically localized to the PVN are mediating the activation of these multiple pathways, such has been found for studies in adults using direct intra-PVN injections (Pan and Gilbert, 1992; Osei-Owusu et al., 2005) , (2) the cellular identity (e.g., oxytocin-containing cells in the PVN) of 5-HT 1A receptormediated ERK and Akt phosphorylation, (3) the potential downstream crosstalk between ERK and Akt signaling pathways, or between the kinase pathways and 5-HT 1A receptor-mediated secretion of the respective stress hormones, (4) the effects of drugs demonstrating functional selectivity or biased agonism for these pathways in the developing brain, (5) the full time course of 5-HT 1A receptor-mediated responses in the peripubertal PVN, and (6) the roles of one or both of these kinase pathways in depressive behaviors and the actions of antidepressant drugs, as previously demonstrated in the adult (Duman et al., 2007) . The present study demonstrating the concomitant activation of multiple kinases and neuroendocrine responses by 5-HT 1A receptors establishes the basis for subsequent important studies along such lines.
Conclusions
We report here the first in vivo demonstration of 5-HT 1A receptor-mediated stimulation of plasma oxytocin and adrenocorticotropic hormone (ACTH) responses and concomitant elevation of phosphorylated extracellular signal-regulated kinase (pERK) and protein kinase B (pAkt) in the peripubertal rat hypothalamic PVN. The two kinase pathways have been implicated in various aspects of growth, differentiation, and mood disorders. We have demonstrated that these pathways in the hypothalamic PVN are established prior to sexual maturation and are similar to those in adults; however, there are some differences in the magnitude and time course of some 5-HT 1A receptor-mediated responses. We also report a 5-HT 1A receptor-mediated inhibition of ERK phosphorylation in peripubertal hippocampus that is similar to that observed in adults. Further studies are required to determine the cellular identity of the kinases in the PVN that are activated by 5-HT 1A receptors, the role that one or both of these kinases may play in 5-HT 1A receptor-mediated hormone secretion, and the contributions of these kinases to SSRI-induced neuroadaptations in neuroendocrine modulation. These findings highlight the importance of further studies investigating the mechanisms of serotonergic signaling in hypothalamus and the role(s) these kinases may play in preclinical models of depression and the effects of antidepressant drugs at both immature and adult ages. 
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